Targeting of calcitonin gene-related peptide action as a new strategy for migraine treatment

Olga Kuzawińska; Krzysztof Lis; Grzegorz Cessak; Dagmara Mirowska-Guzel; Ewa Bałkowiec-Iskra

doi:10.1016/j.pjnns.2016.07.012

Targeting of calcitonin gene-related peptide action as a new strategy for migraine treatment

Neurol Neurochir Pol. 2016 Nov-Dec;50(6):463-467. doi: 10.1016/j.pjnns.2016.07.012. Epub 2016 Aug 10.

Authors

Olga Kuzawińska¹, Krzysztof Lis¹, Grzegorz Cessak², Dagmara Mirowska-Guzel³, Ewa Bałkowiec-Iskra⁴

Affiliations

¹ Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland.
² Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland; The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Warsaw, Poland.
³ Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland; 2nd Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland.
⁴ Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland; The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Warsaw, Poland. Electronic address: ebalkowiec@wum.edu.pl.

PMID: 27553188
DOI: 10.1016/j.pjnns.2016.07.012

Abstract

Migraine is a chronic, recurrent disorder, characterized by attacks of severe pain, affecting around 1% of adult population. Many studies suggest, that trigeminovascular system plays a key role in pathogenesis of migraine and other primary headaches. Calcitonin gene-related peptide (CGRP) is an endogenous substance, which is regarded a key mediator released from trigeminovascular system after stimulation of sensory nerve endings, responsible for dilatation of peripheral vessels and sensory transmission. CGRP is and extensively studied peptide as one of the most promising targets in migraine drug research. In the article we focus on the role of CGRP in the pathophysiology of migraine and present current data on CGRP antagonists and CGRP monoclonal antibodies.

Keywords: Calcitonin gene-related peptide; Calcitonin gene-related peptide antagonists; Migraine; Monoclonal antibodies.

Publication types

Review

MeSH terms

Antibodies, Monoclonal / therapeutic use
Azepines / therapeutic use*
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Calcitonin Gene-Related Peptide / antagonists & inhibitors*
Calcitonin Gene-Related Peptide / metabolism
Dipeptides / therapeutic use*
Heterocyclic Compounds, 4 or More Rings / therapeutic use
Humans
Imidazoles / therapeutic use*
Migraine Disorders / drug therapy*
Migraine Disorders / metabolism
Molecular Targeted Therapy
Piperazines
Quinazolines / therapeutic use*
Spiro Compounds / therapeutic use

Substances

2-(8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro(4.5)dec-9-yl)-N-(2'-oxo-1,1',2',3-tetrahydrospiro(indene-2,3'-pyrrolo(2,3-b)pyridin)-5-yl)acetamide
Antibodies, Monoclonal
Azepines
BMS-846372
Bridged Bicyclo Compounds, Heterocyclic
Dipeptides
Heterocyclic Compounds, 4 or More Rings
Imidazoles
Piperazines
Quinazolines
Spiro Compounds
fremanezumab
telcagepant
Calcitonin Gene-Related Peptide
olcegepant